礼来Muvalaplin片启动III期临床适应症为降低伴Lp(a)水平升高患者MACE发生风险

新浪财经2025-09-01

药物临床试验登记与信息公示平台数据显示，Eli Lilly and Company、礼来苏州制药有限公司、Lilly del Caribe, Inc.的一项在伴有脂蛋白(a)水平升高且发生过动脉粥样硬化性心血管事件或发生首次动脉粥样硬化性心血管事件风险升高成人中评价Muvalaplin对主要不良心血管事件影响的III期、随机、双盲、安慰剂对照研究 - MOVE - Lp(a)已启动。临床试验登记号...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2564898466?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-01 12:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2564898466","market":"us","top_or_hot":-1,"title":"礼来Muvalaplin片启动III期临床 适应症为降低伴Lp(a)水平升高患者MACE发生风险","media":"新浪财经","content":"<div>\n<p>药物临床试验登记与信息公示平台数据显示，Eli Lilly and Company、礼来苏州制药有限公司、Lilly del Caribe, Inc.的一项在伴有脂蛋白(a)水平升高且发生过动脉粥样硬化性心血管事件或发生首次动脉粥样硬化性心血管事件风险升高成人中评价Muvalaplin对主要不良心血管事件影响的III期、随机、双盲、安慰剂对照研究 - MOVE - Lp(a)已启动。临床试验登记号...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来Muvalaplin片启动III期临床 适应症为降低伴Lp(a)水平升高患者MACE发生风险</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来Muvalaplin片启动III期临床 适应症为降低伴Lp(a)水平升高患者MACE发生风险\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-01 12:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>药物临床试验登记与信息公示平台数据显示，Eli Lilly and Company、礼来苏州制药有限公司、Lilly del Caribe, Inc.的一项在伴有脂蛋白(a)水平升高且发生过动脉粥样硬化性心血管事件或发生首次动脉粥样硬化性心血管事件风险升高成人中评价Muvalaplin对主要不良心血管事件影响的III期、随机、双盲、安慰剂对照研究 - MOVE - Lp(a)已启动。临床试验登记号...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","article_id":"2564898466","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2564898466","pubTimestamp":1756701060,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"本次试验主要目的为在伴有Lp水平升高且发生过ASCVD事件或发生首次ASCVD事件风险升高的成人参与者中评价Muvalaplin对主要不良心血管事件影响。Muvalaplin片为化学药物，适应症为在伴Lp水平升高且已确诊CVD或发生首次CVE风险升高的患者中，降低MACE的发生风险。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4599":"减肥药","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","LU0079474960.USD":"联博美国增长基金A","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","III":"信息服务","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LLY":"礼来","MACE":"Mace Security International, Inc.","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","Y":"Alleghany Corp","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0385154629.USD":"贝莱德营养科学基金A2"},"translate_title":"Eli Lilly's Muvalaplin tablets initiate phase III clinical indication to reduce the risk of MACE in patients with elevated Lp (a) levels","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MACE":1,"III":1,"LLY":1,"Y":0.9},"content_text":"药物临床试验登记与信息公示平台数据显示，Eli Lilly and Company、礼来苏州制药有限公司、Lilly del Caribe, Inc.的一项在伴有脂蛋白(a)水平升高且发生过动脉粥样硬化性心血管事件或发生首次动脉粥样硬化性心血管事件风险升高成人中评价Muvalaplin对主要不良心血管事件影响的III期、随机、双盲、安慰剂对照研究 - MOVE - Lp(a)已启动。临床试验登记号为CTR20253466，首次公示信息日期为2025年9月1日。该药物剂型为片剂，用法为口服，每日一次，口服1片。本次试验主要目的为在伴有Lp(a)水平升高且发生过ASCVD事件或发生首次ASCVD事件风险升高的成人参与者中评价Muvalaplin对主要不良心血管事件影响。Muvalaplin片为化学药物，适应症为在伴Lp(a)水平升高且已确诊CVD或发生首次CVE风险升高的患者中，降低MACE的发生风险。Lp(a)升高是动脉粥样硬化性心血管疾病独立危险因素，MACE包括心血管死亡、心肌梗死等，可通过检测Lp(a)水平及评估心血管病史诊断。本次试验主要终点指标包括评价在降低MACE - 4复合终点的风险方面，Muvalaplin是否优效于安慰剂；次要终点指标包括评价在降低Lp(a)水平方面，Muvalaplin是否优效于安慰剂；评价Muvalaplin是否优效于安慰剂，降低MACE - 3复合终点、改良MACE - 3复合终点、冠状动脉MACE - 3复合终点、MACE - 3 + MALE复合终点的风险。目前，该实验状态为进行中（尚未招募），目标入组人数为国内650人、国际10450人。风险提示：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系biz@staff.sina.com.cn。责任编辑：小浪快报","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564898466","isCrawlerRequest":true}

礼来Muvalaplin片启动III期临床 适应症为降低伴Lp(a)水平升高患者MACE发生风险

精彩评论

礼来Muvalaplin片启动III期临床适应症为降低伴Lp(a)水平升高患者MACE发生风险